New liver drug candidate AD-230 enters first human tests

NCT ID NCT07521241

Not yet recruiting Knowledge-focused Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test a new drug called AD-230 in 52 healthy adults to see how the body processes it and whether it is safe. The study uses a crossover design where each participant receives both AD-230 and a related version. Results will help decide if AD-230 should move into larger studies for chronic liver disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD-230
What this could lead to: If successful, this trial will provide essential safety and dosing data to guide future studies of AD-230 for chronic liver disease.
What could go wrong: This is a very early Phase 1 study in healthy volunteers, not patients. It only measures drug levels and short-term safety, not whether the drug actually treats liver disease. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE (CLD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LIVER DISEASE (CLD)

Contacts and locations

Locations

Kyungpook National university hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.